These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Hepatorenal syndrome. Guevara M; Ginès P Dig Dis; 2005; 23(1):47-55. PubMed ID: 15920325 [TBL] [Abstract][Full Text] [Related]
31. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Moreau R; Lebrec D Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352 [TBL] [Abstract][Full Text] [Related]
32. Renal replacement therapy in special settings: extracorporeal support devices in liver failure. Cerdá J; Tolwani A; Gibney N; Tiranathanagul K Semin Dial; 2011; 24(2):197-202. PubMed ID: 21517988 [TBL] [Abstract][Full Text] [Related]
34. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis. Gentilini P; Laffi G; La Villa G; Raggi VC Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019 [TBL] [Abstract][Full Text] [Related]
35. Terlipressin in hepatorenal syndrome: Evidence for present indications. Rajekar H; Chawla Y J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521 [TBL] [Abstract][Full Text] [Related]
37. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Møller S; Bendtsen F; Henriksen JH Scand J Gastroenterol; 2005 May; 40(5):491-500. PubMed ID: 16036500 [TBL] [Abstract][Full Text] [Related]
38. Hepatorenal syndrome. Cárdenas A; Arroyo V Ann Hepatol; 2003; 2(1):23-9. PubMed ID: 15094702 [TBL] [Abstract][Full Text] [Related]
39. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival? Gülberg V; Gerbes AL Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953 [TBL] [Abstract][Full Text] [Related]